The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The medical records of patients with hematogenous candidiasis at M. D. Anderson Cancer Center (Houston) between 1988 and 1992 were retrospectively reviewed. There were 491 episodes of infection (6 per 1,000 admissions), 79% of which occurred outside the intensive care unit setting. A significant decrease in incidence was observed among patients with leukemia over the study period, together with a relative decrease in Candida albicans and Candida tropicalis infections and an increase in Candida krusei and possibly Candida glabrata infections. In the multivariate analysis, fluconazole prophylaxis provided strong protection against the development of C. tropicalis infection (odds ratio [OR] = 0.08) and C. albicans infection (OR = 0.15), in comparison with protection against infections due to other species, but it was the single most important determinant for the relative increase in C. krusei (OR = 27.07) and C. glabrata (OR = 5.08) infections. In conclusion, there has been a substantial shift in the epidemiology of hematogenous candidiasis caused by different Candida species in recent years. Fluconazole appears to be playing a major role in this observed shift.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Changes in the species distributions of bloodstream isolates in hospitalized patients outside the ICU setting have also been reported (1, 20, 30).”
In the citing paper
“The effects of prior fluconazole use on the distribution of various Candida species causing BSI and, in particular, on the emergence of C. glabrata infections were previously demonstrated for patients with hematologic malignancies (1, 18), although other confounding risk factors have also been described (47, 48).”
In the citing paper
“Other North American and European investigators confirmed these observations in larger hospital settings [10, 11, 13, 20, 22, 25, 26].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [10]
In the citing paper
“compared to other Candida species infections, the mortality rate associated with C. glabrata is the highest [19].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [19]
In the citing paper
“Although the association with fluconazole use and increased isolation of C. glabrata is well known (1, 10, 148, 311, 319), the evidence is strongest for cancer centers and less so for individual nonspecialty hospitals (11, 33, 131, 145, 147, 259).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [1]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of Therapy
Horn, R., Wong, B., Kiehn, T. E., & Armstrong, D. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.5.646 · Cited by 480
Candida tropicalis: A Major Pathogen in Immunocompromised Patients
WINGARD, J. R., MERZ, W. G., & SARAL, R. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-4-539 · Cited by 294
Systemic candidiasis in cancer patients.
Maksymiuk, A. W., Thongprasert, S., Hopfer, R. L., Luna, M. D. V., Fainstein, V., & Bodey, G. P. (1984) · PubMed · Cited by 271
Fluconazole and Candida krusei Fungemia
Girmenia, C., Pagano, L., Leone, G., & Martino, P. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.18.2267 · Cited by 19
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
“Meta-analysis of antifungal prophylaxis in nonneutropenic critically ill and surgical patients: comparison of five recent systematic reviews Authors (reference) No. of studies includeda Total no. of patients Patient type Yr Antifungal agent(s) b (no. of studies) Effects of prophylaxis onc: IFI Mortality Resistance Pla…”
BackgroundInfluentialCurrent and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
“, which are becoming increasingly prevalent, is problematic because of the increasing incidence of non-albicans species (1, 188) and the emergence of non-albicans isolates resistant to both amphotericin B and the newer azoles (172).”
BackgroundCandida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055
“One study, however, found that neutrophil count rather than underlying disease was the most important risk factor (3).”
BackgroundResultSilva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00278.x · Cited by 969
“This is extremely important, because, compared with other NCAC species infection, the mortality rate associated with C. glabrata is the highest (Abi-Said et al., 1997; Krcmery, 1999b).”
ResultHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“tropicalis [34–41].”
Self-citation
Metadata
- Authors
- Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Raad, Issam
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-06
- Volume
- 24
- Issue
- 6
- Pages
- 1122-1128
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2095696028
- Cited by
- 755
- References
- 4
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 5 · 2022: 11 · 2021: 3 · 2020: 14 · 2019: 9 · 2018: 8 · 2017: 18 · 2016: 10 · 2015: 21 · 2014: 28 · 2013: 17 · 2012: 35
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida species, Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, fluconazole prophylaxis, leukemia, incidence trends, opportunistic fungal infection, cancer patients
- MeSH terms
- Adult, Aged, Candida, Candidiasis, Female, Humans, Male, Middle Aged, Retrospective Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.